White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
One Percent Rule Checklist For Safer Forex Trading Risk 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
With the world impacted by the pandemic, the goal to bring medical alternatives to market first is now the utmost priority for many pharmaceutical companies. In support of finding these solutions, Samsung Biologics has signed a contract manufacturing agreement with GlaxoSmithKline (GSK) to produce neutralizing antibodies for COVID-19.
In April, GSK invested $250 million in the research of Vir Biotechnology to create a collaborative COVID-19 antibody treatment. With no approved treatment currently on the market, the collaborative efforts are looking at antibodies of recovered patients to see how they can help new patients recover. This is different than plasma therapy with antibodies because Vir is selecting key antibodies from the plasma to establish a process easier to administer on a large scale, making it more efficient to reach a global market. Samsung Biologics looks to help speed up that solution by offering its manufacturing service to GSK
The boost of outsourcing contracts that Samsung Biologics has gained during the COVID-19 pandemic can be largely chalked up to their unwavering drive towards quality and innovation. The company prides itself on offering a wide range of services, so clients need fewer jumps in their production and testing process.
Samsung Biologics also recently announced plans for a fourth plant expansion—estimated to invest around 2 billion USD—which will maximize operational efficiency, scale up its development and manufacturing capabilities, and through a second bio complex, foster biotech companies with an Open Innovation Center and global R&D facility.
In a time where resilient supply chains and pharmaceutical solutions are desperately needed, Samsung Biologics is filling the gap. Clients can use the large capacity and proven regulatory track record to place their products in good hands for a faster-to-market turnaround. The company also works to cut excess production time and create a development process that works best for the client. The goal is to get quality products into the hands of the patients that desperately need them.
This article does not necessarily reflect the opinions of the editors or management of EconoTimes
